Haier Biomedical Accelerates Global Leadership in Life Sciences with Record Earnings and Innovative AI Technologies
Haier Biomedical is breaking new ground in the life sciences sector, exemplified by the release of its 2025 annual report, which reveals an impressive revenue of 2.33 billion yuan, translating to approximately 340.77 million USD. Notably, overseas revenue surged by 17.9% year-on-year, contributing to 36% of total revenue – a historic achievement for the company. Amidst challenging global trade dynamics, Haier Biomedical has demonstrated robust growth across its international business divisions.
The company has transitioned from a focus on mere product exports to a broader strategy of brand globalization. In 2025, Haier Biomedical experienced significant compound growth in international markets, achieving double-digit revenue increases in regions including Europe, Asia-Pacific, the Americas, and Africa. The Asia-Pacific region marked a substantial 26.0% growth, while Europe notched a remarkable 16.0% increase.
Furthermore, Haier Biomedical has rolled out a forward-looking strategic blueprint called "growth leapfrogging," which focuses on three primary avenues: market leap, industry leap, and model leap. This ambitious approach aims to cultivate a premier integrated platform for life science tools and smart productivity that resonates globally.
The company's revenue structure has shown substantial optimization, with emerging market sectors and international operations recognized as pivotal growth engines. Significant business segments like smart medication, blood technology, and laboratory solutions now account for 48.5% of total revenue, reflecting an 8.8% year-on-year increase. The firm’s advanced ultra-low and low-temperature biomedical freezers have also claimed the top market share in six countries, including Italy, while leading domestic competitors in exporting smart medication dispensing solutions.
A remarkable 15% of total revenue is attributed to AI-powered applications, marking a 2.5 percentage points growth from the prior year. Haier Biomedical has established a multi-tiered AI infrastructure comprising large models, AI agents, and AI terminals, facilitating the development of 17 proprietary agents integrated into 13 automated solutions. AI-enabled pharmacies have revolutionized direct dispensing rates, achieving an impressive 80% – significantly above industry standards.
The firm’s fully automated cell workstation has garnered accolades, including a prestigious award for disruptive technology from the Ministry of Industry and Information Technology. Additionally, a fully enclosed automated cell expansion system is in clinical trial phases, contributing to advancements in bioartificial liver therapies.
Haier Biomedical's pioneering initiatives have seen its plasma separation system become the first Chinese solution to attain the EU MDR certification. The company’s "Ultra Series" ultra-low temperature biomedical freezers have achieved remarkable energy efficiency, with the top eight products in the ENERGY STAR program, all attributed to Haier Biomedical.
In terms of research and development, the company invested 320 million yuan (approximately 46.82 million USD) in 2025, achieving a remarkable 50% increase in new invention patents, totaling 1,620 patents. Product launch rates improved by 11%, while 11 solutions reached industry-first status. Notably, Haier Biomedical has set a benchmark by becoming the first in China to master stable 100,000-rpm ultra-high-speed centrifugation technology, overcoming a significant technical bottleneck that bolsters its competitive edge in the market.
On the global stage, Haier Biomedical now holds over 400 international product certifications and collaborates with nearly 80 international organizations, including WHO and UNICEF. Its extensive distribution network encompasses over 800 partners across 160+ countries and regions. Adhering to a "one country, one strategy" methodology, the company has set up subsidiaries in four nations and localized operations in another 18, thereby enhancing rapid delivery and tailored services, which ultimately fosters robust customer relationships.
Looking to the future, Haier Biomedical has articulated strategic targets, dubbed the three-year "543" plan, which aims to elevate global penetration through localized operations, achieve over 50% of revenue from overseas, expand its strategic industry foothold through platform-based growth, and drive future leadership via AI innovations accounting for over 30% of revenue.
With its commitment to fostering localized development, leveraging AI innovation, and pursuing strategic mergers and acquisitions, Haier Biomedical is poised to achieve a comprehensive transformation in revenue structures, profit quality, and valuation fundamentals. Through these initiatives, the company aspires to emerge as a world-leading entity in integrated life science tools and intelligent productivity platforms.
The company has transitioned from a focus on mere product exports to a broader strategy of brand globalization. In 2025, Haier Biomedical experienced significant compound growth in international markets, achieving double-digit revenue increases in regions including Europe, Asia-Pacific, the Americas, and Africa. The Asia-Pacific region marked a substantial 26.0% growth, while Europe notched a remarkable 16.0% increase.
Furthermore, Haier Biomedical has rolled out a forward-looking strategic blueprint called "growth leapfrogging," which focuses on three primary avenues: market leap, industry leap, and model leap. This ambitious approach aims to cultivate a premier integrated platform for life science tools and smart productivity that resonates globally.
The company's revenue structure has shown substantial optimization, with emerging market sectors and international operations recognized as pivotal growth engines. Significant business segments like smart medication, blood technology, and laboratory solutions now account for 48.5% of total revenue, reflecting an 8.8% year-on-year increase. The firm’s advanced ultra-low and low-temperature biomedical freezers have also claimed the top market share in six countries, including Italy, while leading domestic competitors in exporting smart medication dispensing solutions.
A remarkable 15% of total revenue is attributed to AI-powered applications, marking a 2.5 percentage points growth from the prior year. Haier Biomedical has established a multi-tiered AI infrastructure comprising large models, AI agents, and AI terminals, facilitating the development of 17 proprietary agents integrated into 13 automated solutions. AI-enabled pharmacies have revolutionized direct dispensing rates, achieving an impressive 80% – significantly above industry standards.
The firm’s fully automated cell workstation has garnered accolades, including a prestigious award for disruptive technology from the Ministry of Industry and Information Technology. Additionally, a fully enclosed automated cell expansion system is in clinical trial phases, contributing to advancements in bioartificial liver therapies.
Haier Biomedical's pioneering initiatives have seen its plasma separation system become the first Chinese solution to attain the EU MDR certification. The company’s "Ultra Series" ultra-low temperature biomedical freezers have achieved remarkable energy efficiency, with the top eight products in the ENERGY STAR program, all attributed to Haier Biomedical.
In terms of research and development, the company invested 320 million yuan (approximately 46.82 million USD) in 2025, achieving a remarkable 50% increase in new invention patents, totaling 1,620 patents. Product launch rates improved by 11%, while 11 solutions reached industry-first status. Notably, Haier Biomedical has set a benchmark by becoming the first in China to master stable 100,000-rpm ultra-high-speed centrifugation technology, overcoming a significant technical bottleneck that bolsters its competitive edge in the market.
On the global stage, Haier Biomedical now holds over 400 international product certifications and collaborates with nearly 80 international organizations, including WHO and UNICEF. Its extensive distribution network encompasses over 800 partners across 160+ countries and regions. Adhering to a "one country, one strategy" methodology, the company has set up subsidiaries in four nations and localized operations in another 18, thereby enhancing rapid delivery and tailored services, which ultimately fosters robust customer relationships.
Looking to the future, Haier Biomedical has articulated strategic targets, dubbed the three-year "543" plan, which aims to elevate global penetration through localized operations, achieve over 50% of revenue from overseas, expand its strategic industry foothold through platform-based growth, and drive future leadership via AI innovations accounting for over 30% of revenue.
With its commitment to fostering localized development, leveraging AI innovation, and pursuing strategic mergers and acquisitions, Haier Biomedical is poised to achieve a comprehensive transformation in revenue structures, profit quality, and valuation fundamentals. Through these initiatives, the company aspires to emerge as a world-leading entity in integrated life science tools and intelligent productivity platforms.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.